Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, China.
Department of Anatomy and Molecular Embryology, Institute of Anatomy, Ruhr-University Bochum, 44801, Bochum, Germany.
J Hematol Oncol. 2018 Jul 4;11(1):91. doi: 10.1186/s13045-018-0629-x.
T cell senescence has been recognized to play an immunosuppressive role in the aging population and cancer patients. Strategies dedicated to preventing or reversing replicative and premature T cell senescence are required to increase the lifespan of human beings and to reduce the morbidity from cancer. In addition, overcoming the T cell terminal differentiation or senescence from lymphoma and leukemia patients is a promising approach to enhance the effectiveness of adoptive cellular immunotherapy (ACT). Chimeric antigen receptor T (CAR-T) cell and T cell receptor-engineered T (TCR-T) cell therapy highly rely on functionally active T cells. However, the mechanisms which drive T cell senescence remain unclear and controversial. In this review, we describe recent progress for restoration of T cell homeostasis from age-related senescence as well as recovery of T cell activation in hematological malignancies.
T 细胞衰老已被认为在老年人群体和癌症患者中发挥免疫抑制作用。需要专门的策略来预防或逆转复制性和过早的 T 细胞衰老，以延长人类的寿命并降低癌症的发病率。此外，克服淋巴瘤和白血病患者的 T 细胞终末分化或衰老，是增强过继细胞免疫治疗（ACT）效果的一种有前途的方法。嵌合抗原受体 T（CAR-T）细胞和 T 细胞受体工程化 T（TCR-T）细胞治疗高度依赖于功能活跃的 T 细胞。然而，导致 T 细胞衰老的机制尚不清楚且存在争议。在这篇综述中，我们描述了从与年龄相关的衰老中恢复 T 细胞动态平衡以及恢复血液恶性肿瘤中 T 细胞激活的最新进展。
